Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals Of The Week Gets Better Connected, Dips A Toe In Digital Health

Executive Summary

Digital health promises to transform the quality of health care and reduce costs, but it is not quite yet in a position to help out governments and other payers struggling to meet the demands put on their health care systems. Plus, news of deals between AstraZeneca and Roche, MorphoSys and Celgene, Aspen and Merck, and more.

You may also be interested in...

A New Class Wanted For New York Digital Health Accelerator

The first nine-month incubator program hosted by the NYeC and PFNYC was a success, helping eight companies get a better footing in the New York economy, gain clients and launch 17 pilot programs that have led to job creation and better technological tools for state hospital systems.

Immunocore Adds GlaxoSmithKline To Its Growing List Of Partners

The British biotech has found validation in two recent partnerships for its cancer immunotherapy platform, while gaining the resources to continue developing its lead compound on its own.

GSK Negotiating Potential $1 Billion Sale Of Two Thrombosis Drugs To Aspen

Reflecting its aim to jettison older products with declining sales, GlaxoSmithKline is considering an offer from South Africa-based generics maker Aspen Pharmacare for its branded heart medicines Arixtra and Fraxiparine and a related manufacturing site in France.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts